Clinical Trial Update: Safety and Tolerability Study of Mesenchymal Stem Cells, HeXell-2020, in Elderly Subjects With Mild to Moderate Frailty Syndrome [Phase 1]

View source ↗

Summary

A Phase 1 safety and tolerability trial of HeXell-2020 Mesenchymal Stem Cells in elderly adults with frailty syndrome, sponsored by Hexun Biosciences; the study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Frailty Syndrome

Drugs mentioned

• HeXell-2020 Mesenchymal Stem Cells (Mesenchymal stem cells)

Snippet

Sponsor: Hexun Biosciences Co., LTD. | Conditions: Frailty in Older Adults | Phase 1 | Status: NOT_YET_RECRUITING